AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1536215 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg micronized 17 beta-estradiol
Number of subjects: 51
Study 1536215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1536215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg micronized 17 beta-estradiol (after double-blind phase)
Number of subjects: 51
Study 1536215 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17 beta-estradiol (previously used)
Number of subjects: 51
Study 1536215 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 51
Study 6369979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral nonabsorbable antibiotics
Number of subjects: 0
Study 6369979 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 0
Study 6369979 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31008751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg
Number of subjects: 64
Study 31008751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 64
Study 31008751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 64
Study 31008751 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 0 µg/kg (control)
Number of subjects: 64
Study 31008751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 64
Study 28820320 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Fibrin (PRF) with open flap debridement (OFD)
Number of subjects: 17
Study 28820320 — intervention group
Group type: COMPARATOR
Intervention: Control group (OFD alone)
Number of subjects: 17
Study 26363333 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 162
Study 26363333 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 162
Study 24616335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 1759
Study 24616335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) or Amlodipine (5 mg)
Number of subjects: 1759
Study 24616335 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy (Aliskiren + Hydrochlorothiazide or Amlodipine)
Number of subjects: 1759
Study 24616335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1759
Study 22081150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 80
Study 22081150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 80
Study 22081150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg bevacizumab
Number of subjects: 80
Study 22081150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bevacizumab)
Number of subjects: 80
Study 19639211 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of carboplatin and docetaxel (A1)
Number of subjects: 83
Study 19639211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of carboplatin and docetaxel (A2)
Number of subjects: 83
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported community-acquired complicated course of UTIs
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above 60 years
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic use of antibiotics
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 6 physician contacts in previous year
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization in previous year
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal disease
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence of urine
Number of subjects: 1151
Study 17203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 1151
Study 15640536 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing (FT)
Number of subjects: 61
Study 15640536 — intervention group
Group type: COMPARATOR
Intervention: Selective functional testing (FT)
Number of subjects: 61
Study 10715251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 208
Study 10715251 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH)
Number of subjects: 208
Study 9370765 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual (video) resources
Number of subjects: 104
Study 9370765 — intervention group
Group type: COMPARATOR
Intervention: Oral resources
Number of subjects: 104
Study 1397671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (UDCG 115)
Number of subjects: 8
Study 1397671 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 2409371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study 2409371 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 26
Study 2409371 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 26
Study 30638396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii UBBC-07
Number of subjects: 0
Study 30638396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29293018 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner's scent
Number of subjects: 96
Study 29293018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stranger's scent
Number of subjects: 96
Study 29293018 — intervention group
Group type: COMPARATOR
Intervention: Neutral scent
Number of subjects: 96
Study 27566848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20
Study 27566848 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 22795164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg/kg dexamethasone intravenously at the beginning of the operation (Group I)
Number of subjects: 60
Study 22795164 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation and 24 hours after (Group II)
Number of subjects: 60
Study 22795164 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation, before osteotomy, and 24 hours after (Group III)
Number of subjects: 60
Study 22795164 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone or controlled hypotension (Group IV - Control)
Number of subjects: 60
Study 20307224 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 0
Study 20307224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0
Study 20307224 — intervention group
Group type: COMPARATOR
Intervention: First-generation 5-HT3RAs
Number of subjects: 0
Study 18206133 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback training in combination with ergonomic counselling (Mfb/EC)
Number of subjects: 36
Study 18206133 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic counselling alone (EC)
Number of subjects: 36
Study 16897249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin (3 ml) combined with saline (3 ml)
Number of subjects: 15
Study 16897249 — intervention group
Group type: COMPARATOR
Intervention: 1% Mepivacaine (6 ml)
Number of subjects: 15
Study 12916011 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 126
Study 12916011 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+ddI
Number of subjects: 126
Study 12916011 — intervention group
Group type: COMPARATOR
Intervention: AZT+3TC
Number of subjects: 126
Study 10954955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice daily for 5 days)
Number of subjects: 586
Study 10954955 — intervention group
Group type: COMPARATOR
Intervention: Loracarbef (400 mg twice daily for 7 days)
Number of subjects: 586
Study 10954955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 586
Study 10954955 — intervention group
Group type: COMPARATOR
Intervention: Loracarbef
Number of subjects: 586
Study 8769695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea and interferon alpha
Number of subjects: 0
Study 8769695 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 0
Study 1376577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/Metronidazole combination
Number of subjects: 100
Study 1376577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 100
Study 1376577 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 100
Study 1376577 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 100
Study 1376577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 100
Study 2872060 — intervention group
Group type: EXPERIMENTAL
Intervention: CM57755
Number of subjects: 10
Study 2872060 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 10
Study 2872060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29570512 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol (1 g three times a day)
Number of subjects: 46
Study 29570512 — intervention group
Group type: COMPARATOR
Intervention: Noneffervescent paracetamol
Number of subjects: 46
Study 29570512 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol
Number of subjects: 46
Study 26868270 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study 26868270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking (7-day point prevalence)
Number of subjects: 0
Study 26868270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking (30-day point prevalence)
Number of subjects: 0
Study 24903062 — intervention group
Group type: EXPERIMENTAL
Intervention: baby-CIMT
Number of subjects: 0
Study 24903062 — intervention group
Group type: COMPARATOR
Intervention: baby-massage
Number of subjects: 0
Study 22333738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling session on alcohol risk reduction
Number of subjects: 0
Study 22333738 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 0
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg/day
Number of subjects: 137
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 100 mg/day
Number of subjects: 137
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 137
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 137
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 137
Study 20466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (various doses)
Number of subjects: 137
Study 20466589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 18603250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of 5 mL of 1% lignocaine 2 minutes prior to the procedure
Number of subjects: 100
Study 18603250 — intervention group
Group type: COMPARATOR
Intervention: Oral naproxen 375 mg self-administered 1 hour prior to HSG
Number of subjects: 100
Study 19204604 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, mixed-type exercise program (20 sessions over 12 weeks)
Number of subjects: 32
Study 19204604 — intervention group
Group type: COMPARATOR
Intervention: Control group continued habitual activities
Number of subjects: 32
Study 16160876 — intervention group
Group type: EXPERIMENTAL
Intervention: SR bupropion (300 mg/day)
Number of subjects: 23
Study 16160876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16160876 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoke
Number of subjects: 23
Study 16160876 — intervention group
Group type: EXPERIMENTAL
Intervention: SR bupropion
Number of subjects: 23
Study 11693589 — intervention group
Group type: EXPERIMENTAL
Intervention: Child training treatment group (CT) utilizing the Incredible Years Dinosaur Social Skills and Problem Solving Curriculum
Number of subjects: 99
Study 11693589 — intervention group
Group type: EXPERIMENTAL
Intervention: Child training treatment group (CT)
Number of subjects: 99
Study 11693589 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (CON)
Number of subjects: 99
Study 9395155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bech-Rafaelsen Mania Scale (MAS)
Number of subjects: 100
Study 9395155 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bech-Rafaelsen Mania Scale (MAS-M)
Number of subjects: 100
Study 9395155 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS-M
Number of subjects: 100
Study 8116059 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin A
Number of subjects: 235
Study 8116059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 8116059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 235
Study 3553455 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin and gentamicin) administered in the immediate preoperative and intraoperative periods
Number of subjects: 846
Study 3553455 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 846
Study 3553455 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin and gentamicin)
Number of subjects: 846
Study 12068839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 187
Study 12068839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 12068839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 187
Study 30160499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk drinking during treatment
Number of subjects: 877
Study 30160499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mostly abstinent during treatment
Number of subjects: 877
Study 30160499 — intervention group
Group type: COMPARATOR
Intervention: Heavy drinking during treatment
Number of subjects: 877
Study 27916914 — intervention group
Group type: EXPERIMENTAL
Intervention: Private sector service delivery (PSSD) of urine-diverting dry latrines
Number of subjects: 0
Study 27916914 — intervention group
Group type: COMPARATOR
Intervention: Government standard delivery (GSD) of cistern-flush toilets or ventilated improved pit latrines
Number of subjects: 0
Study 27916914 — intervention group
Group type: EXPERIMENTAL
Intervention: Private sector service delivery (PSSD)
Number of subjects: 0
Study 24906406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy delivered by healthcare assistants
Number of subjects: 0
Study 24906406 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22340549 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated transradial coronary intervention (r‐TRI)
Number of subjects: 423
Study 22340549 — intervention group
Group type: COMPARATOR
Intervention: Initial transradial intervention (i‐TRI)
Number of subjects: 423
Study 21287460 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine cream for 4 weeks
Number of subjects: 110
Study 21287460 — intervention group
Group type: COMPARATOR
Intervention: Stool softeners and 2% lidocaine cream for 4 weeks
Number of subjects: 110
Study 18387065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 0
Study 18387065 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime + Amikacin + Metronidazole (control)
Number of subjects: 0
Study 15983523 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) diet
Number of subjects: 15
Study 15983523 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid (SFA) diet
Number of subjects: 15
Study 12093304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 231
Study 12093304 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin
Number of subjects: 231
Study 10710823 — intervention group
Group type: EXPERIMENTAL
Intervention: New Cyclosporine A microemulsion formulation
Number of subjects: 24
Study 10710823 — intervention group
Group type: COMPARATOR
Intervention: Reference market standard Cyclosporine A microemulsion
Number of subjects: 24
Study 8964641 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 26
Study 8964641 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 26
Study 2117054 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN patches)
Number of subjects: 0
Study 2117054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6992916 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 388
Study 6992916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 388
Study 6992916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 30836807 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT (20‐40 sessions) plus conventional treatment
Number of subjects: 30
Study 30836807 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 30
Study 30113568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 205
Study 30113568 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 205
Study 26931522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy with uvulopalatopharyngoplasty (TE‐UPPP)
Number of subjects: 42
Study 26931522 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study 24983742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol plus carboxymethyl-β-glucan
Number of subjects: 68
Study 24983742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 22537541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (62 Gy at 3.1 Gy per fraction in 5 weeks) + 9-month androgen deprivation therapy
Number of subjects: 168
Study 22537541 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (80 Gy at 2 Gy per fraction in 8 weeks) + 9-month androgen deprivation therapy
Number of subjects: 168
Study 20397271 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 13
Study 20397271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum
Number of subjects: 13
Study 17999708 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 150
Study 17999708 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.625 mg)
Number of subjects: 150
Study 17999708 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study 16446682 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g creatine monohydrate, 4 times daily for 6 days)
Number of subjects: 23
Study 16446682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored drink without creatine monohydrate)
Number of subjects: 23
Study 16446682 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 23
Study 16446682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 14630885 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Number of subjects: 14
Study 14630885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch meal
Number of subjects: 14
Study 14630885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner meal
Number of subjects: 14
Study 11081314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldactone (200 mg i.v.)
Number of subjects: 21
Study 11081314 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 mg i.v.)
Number of subjects: 21
Study 8671857 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + enalapril (20mg p.o. oad)
Number of subjects: 24
Study 8671857 — intervention group
Group type: COMPARATOR
Intervention: CsA (7.5 mg/kg. b.i.d. in olive oil)
Number of subjects: 24
Study 1315826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (10 mmol/day)
Number of subjects: 0
Study 1315826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (800 mmol/day)
Number of subjects: 0
Study 1315826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet with added potassium (100 mmol/day)
Number of subjects: 0
Study 1315826 — intervention group
Group type: COMPARATOR
Intervention: Baseline (free access to sodium)
Number of subjects: 0
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with nasolacrimal obstruction (NLO)
Number of subjects: 6
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with eyelid closure (EC)
Number of subjects: 6
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with both NLO and EC
Number of subjects: 6
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with neither NLO nor EC
Number of subjects: 6
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% pilocarpine ointment
Number of subjects: 6
Study 4096205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution
Number of subjects: 6
Study 30907209 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 µg of misoprostol (oral or vaginal)
Number of subjects: 253
Study 30907209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mg vitamin B6)
Number of subjects: 253
Study 29233719 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% carbohydrate, 20% fat)
Number of subjects: 164
Study 29233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet (40% carbohydrate, 40% fat)
Number of subjects: 164